Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

As products enter clinic... scientists shown the door

Article Abstract:

The oncology company OSI pharmaceuticals of Melville, NY cut 90 of its employees, mostly in research to save $10-15 million, when it completed the US submission of a new drug application for Tarceva, for the treatment of patients with advanced non-small cell lung cancer. The biotech companies evolve into product development companies and as their lead programs enter human testing, they focus on their resources on the expensive clinical programs that will help them establish a profitable business.

Author: Ratner, Mark
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
United States, Personnel administration, Human resource management, Company personnel management, Pharmaceutical research, OSI Pharmaceuticals Inc., OSIP

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Syrrx acquisition signals maturation of structure-based discovery

Article Abstract:

San Diego-based Syrrx, a high-throughput crystallography-based drug discovery firm for $270 million is acquired by Takeda to open a drug discovery research site outside Japan. Takeda's choice of the company suggests maturation in the application of structural biology as a starting point for drug development.

Author: Ratner, Mark
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Japan, Acquisitions & mergers, Facilities & equipment, Mergers, acquisitions and divestments, Company acquisition/merger, Buildings and facilities, Takeda Chemical Industries Ltd.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Ian Frazer

Article Abstract:

The immunologist, Ian Frazer, director of the Edinburgh University's Diamantina Institute and head of its immunotherapy group, developed the first vaccine, Gardasil to prevent cervical cancer caused by human papilloma virus (HPV).

Author: Ratner, Mark
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Science & research, Pharmaceutical Preparation Manufacturing, Anticancer Drugs, Chemotherapeutic Drugs, Research, Innovations, Antineoplastic agents, Immunologists, Antimitotic agents, Gardasil (Vaccine), Frazer, Ian

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry
Similar abstracts:
  • Abstracts: Care Bears Body Pack; Bear Essentials Shimmer Pack. Canali Men's Fragrance
  • Abstracts: Health Products Hango Hangover Relief Beverage. Ginger People Ginger Soother Beverage. Eshot No More Hangovers Beverage
  • Abstracts: Fruit2O Splashzone Naturally Flavored Water. Trinity Springs Enhanced Waters
  • Abstracts: Organics Canned Cat Food. Iams Cat Food
  • Abstracts: The zinc finger nuclease monopoly. Mice with a human touch. The problem with potency
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.